$2.75
AN2 Therapeutics is a biotechnology business based in the US. AN2 Therapeutics shares (ANTX) are listed on the NASDAQ and all prices are listed in US Dollars. AN2 Therapeutics employs 41 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy AN2 Therapeutics stock
How to buy AN2 Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ANTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy AN2 Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AN2 Therapeutics stock price (NASDAQ: ANTX)
Use our graph to track the performance of ANTX stocks over time.AN2 Therapeutics shares at a glance
Latest market close | $2.91 |
---|---|
52-week range | $1.91 - $22.22 |
50-day moving average | $2.25 |
200-day moving average | $9.23 |
Wall St. target price | $12.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-2.51 |
Is it a good time to buy AN2 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AN2 Therapeutics price performance over time
Historical closes compared with the close of $2.91 from 2024-07-22
1 week (2024-07-17) | -1.69% |
---|---|
1 month (2024-06-24) | 40.58% |
3 months (2024-04-24) | 21.25% |
6 months (2024-01-24) | -85.02% |
1 year (2023-07-24) | -61.61% |
---|---|
2 years (2022-07-22) | -64.64% |
3 years (2021-07-20) | N/A |
5 years (2019-07-20) | N/A |
AN2 Therapeutics financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -42.32% |
Return on equity TTM | -68.38% |
Profit margin | 0% |
Book value | $3.71 |
Market Capitalization | $83.2 million |
TTM: trailing 12 months
AN2 Therapeutics share dividends
We're not expecting AN2 Therapeutics to pay a dividend over the next 12 months.
AN2 Therapeutics share price volatility
Over the last 12 months, AN2 Therapeutics's shares have ranged in value from as little as $1.91 up to $22.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AN2 Therapeutics's is -0.12. This would suggest that AN2 Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, AN2 Therapeutics has bucked the trend.
AN2 Therapeutics overview
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Frequently asked questions
nullWhat percentage of AN2 Therapeutics is owned by insiders or institutions?
Currently 25.371% of AN2 Therapeutics shares are held by insiders and 70.519% by institutions. How many people work for AN2 Therapeutics?
Latest data suggests 41 work at AN2 Therapeutics. When does the fiscal year end for AN2 Therapeutics?
AN2 Therapeutics's fiscal year ends in December. Where is AN2 Therapeutics based?
AN2 Therapeutics's address is: 1800 El Camino Real, Menlo Park, CA, United States, 94027
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
Put options explained
Learn the basics of put options: what they are, how they work and a few examples.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 best day trading platforms of July 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
11 apps like Webull you need to consider
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
7 best ways to invest $10K
Check out our 7 ideas for how to invest $10K to maximize your money.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question